Format

Send to

Choose Destination
PLoS One. 2015 Jun 11;10(6):e0129503. doi: 10.1371/journal.pone.0129503. eCollection 2015.

Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.

Author information

1
Immco Diagnostics, Buffalo, NY, United States of America.
2
Department of Neurology, State University of New York, Buffalo, NY, United States of America.
3
Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, United States of America; Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, United States of America.
4
Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, United States of America.
5
Department of Neurology, State University of New York, Buffalo, NY, United States of America; Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, United States of America.

Abstract

To compare frequencies of autoreactive antibody responses to endogenous disease-associated antigens in healthy controls (HC), relapsing and progressive MS and to assess their associations with clinical and MRI measures of MS disease progression.

METHODS:

The study analyzed 969 serum samples from 315 HC, 411 relapsing remitting MS (RR-MS), 128 secondary progressive MS (SP-MS), 33 primary progressive MS (PP-MS) and 82 patients with other neurological diseases for autoantibodies against two putative MS antigens CSF114(Glc) and KIR4.1a and KIR4.1b and against 24 key endogenous antigens linked to diseases such as vasculitis, systemic sclerosis, rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, polymyositis, scleroderma, polymyositis, dermatomyositis, mixed connective tissue disease and primary biliary cirrhosis. Associations with disability and MRI measures of lesional injury and neurodegeneration were assessed.

RESULTS:

The frequencies of anti-KIR4.1a and anti-KIR4.1b peptide IgG positivity were 9.8% and 11.4% in HC compared to 4.9% and 7.5% in RR-MS, 8.6% for both peptides in SP-MS and 6.1% for both peptides in PP-MS (p = 0.13 for KIR4.1a and p = 0.34 for KIR4.1b), respectively. Antibodies against CSF114(Glc), KIR4.1a and KIR4.1b peptides were not associated with MS compared to HC, or with MS disease progression. HLA DRB1*15:01 positivity and anti-Epstein Barr virus antibodies, which are MS risk factors, were not associated with these putative MS antibodies.

CONCLUSIONS:

Antibody responses to KIR4.1a and KIR4.1b peptides are not increased in MS compared to HC nor associated with MS disease progression. The frequencies of the diverse autoreactive antibodies investigated are similar in MS and HC.

PMID:
26065913
PMCID:
PMC4466031
DOI:
10.1371/journal.pone.0129503
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center